60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced Monday the appointment of Kristian Humer as chief financial officer and principal financial officer, according to a statement filed with the U.S. Securities and Exchange Commission. The biotech company, currently valued at $616 million, holds more cash than debt on its balance sheet with a healthy current ratio of 8.42, according to InvestingPro data. This strong liquidity position comes as the company is quickly burning through cash while pursuing growth opportunities.
Mr. Humer, age 50, most recently served as chief financial officer at Foghorn Therapeutics, Inc. from April 2024 to November 2025. He was previously chief financial officer and chief business officer at Viridian Therapeutics, Inc. from July 2021 to September 2023. Earlier in his career, Mr. Humer held several roles at Citigroup Global Markets Inc., including managing director in the healthcare investment banking group from December 2016 to July 2021. He holds an MBA from Duke University’s Fuqua School of Business and a BA (Hons) in Accounting & Economics from the University of Reading.
Under the terms of his offer letter, Mr. Humer will receive an annual base salary of $520,000 and is eligible for a discretionary annual performance bonus with a target of 40% of his base salary. He will also be granted a stock option to purchase 480,000 shares of the company’s common stock. The agreement includes a sign-on bonus totaling $100,000, payable in two equal installments, subject to continued employment and specific timing conditions.
If Mr. Humer’s employment is terminated without cause or for good reason, he will be eligible for severance benefits equal to nine months of base salary and reimbursement of COBRA premiums for up to nine months. In the event of such a termination within 12 months after a change in control, the severance benefits increase to 12 months of base salary and COBRA premium reimbursement for up to 12 months, along with full vesting acceleration of his outstanding equity awards. These benefits are subject to his execution of a general release and compliance with confidentiality and invention assignment agreements.
There are no arrangements or understandings between Mr. Humer and any other person related to his appointment, and no family relationships or reportable transactions exist between him and the company’s directors or executive officers. This information is based on a press release statement filed with the SEC.
In other recent news, 4D Molecular Therapeutics announced several significant developments. The company reported a current cash position of $372 million, bolstered by a recent deal with Otsuka Pharmaceutical and a capital raise. This deal includes an $85 million upfront payment and cost-sharing of at least $50 million over the next three years, with potential milestone payments of up to $336 million. Additionally, RBC Capital raised its price target for 4D Molecular Therapeutics to $32, citing these funding developments. Leerink Partners also increased its price target to $17 following an exclusive license agreement with Otsuka for the Asia-Pacific region. Furthermore, Morgan Stanley upgraded the company’s stock rating from Underweight to Equalweight, driven by positive clinical trial results for the 4D-150 therapy. These trials showed consistent durability and encouraging safety profiles in treating wet age-related macular degeneration. These recent developments reflect a period of strategic growth and clinical progress for 4D Molecular Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.